Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APL 400-003 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| APL 400-003 | BIOLOGICAL | - |
Inclusion Criteria You may be eligible for this study if you: * Are 18 - 60 years old. * Are HIV-negative and in good health. * Are able to understand how infections such as HIV are spread. * Agree to use effective methods of birth control during the study. Exclusion Criteria You will not be eli...
Top 20 of 28 competitors
APL 400-003 is an investigational monoclonal antibody being studied for HIV infections. It is in Phase 1 clinical development and has been evaluated in completed trials involving HIV-seronegative volunteers. The drug is not approved and remains under investigation for its potential use in HIV.
APL 400-003 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company is conducting clinical research on this investigational monoclonal antibody for HIV infections.
APL 400-003 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, and the drug remains under study for HIV infections.
APL 400-003 has been studied in two completed Phase 1 trials: NCT00002231 and NCT00002232. Both trials evaluated the safety and effects of the drug, also known as GENEVAX-HIV, in HIV-seronegative volunteers in the United States.
Yes, APL 400-003 is also known as GENEVAX-HIV. Clinical trials NCT00002231 and NCT00002232 refer to the drug by this alternative name, and both names describe the same investigational monoclonal antibody for HIV infections.